Cover Image
市場調查報告書

生技藥品的全球市場:2016年∼2026年的趨勢與預測

Biologics Market Trends and Forecasts 2016-2026: Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC)

出版商 Visiongain Ltd 商品編碼 235218
出版日期 內容資訊 英文 274 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生技藥品的全球市場:2016年∼2026年的趨勢與預測 Biologics Market Trends and Forecasts 2016-2026: Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC)
出版日期: 2016年07月20日 內容資訊: 英文 274 Pages
簡介

本報告提供全球生技藥品市場相關調查分析,生技藥品概要,市場預測,次市場預測,主要國家的市場預測,定性分析等系統性資訊。

第1章 報告概要

第2章 生技藥品市場簡介主要的概念

  • 生技藥品:大規模且複雜的產品
  • 生技藥品開發的過程
  • 全球醫藥品市場上生技藥品最暢銷的理由
  • 所謂生技仿製藥
  • 下一代的生技藥品,市場佔有率
  • 境界病例
  • 疫苗市場

第3章 全球生技藥品市場

  • 市場預測
  • 推動市場要素、阻礙因素
  • 高齡化和慢性疾病的增加
  • 暢銷前十名中,有8個是生技藥品
  • 生技藥品佔全球醫藥品市場的19%
  • 生技仿製藥:機會及威脅
  • 阻礙市場成長要素
  • 高成本
  • 也有臨床性有效性無法充分填補價格差距的領域
  • 生技藥品專利的670億美元以上,至2020年專利到期
  • 也有給藥不方便的情況
  • 生技藥品市場:次市場預測

第4章 蛋白質製劑次市場

  • 大規模且最多樣的次市場
  • 蛋白質從19世紀開始利用於醫療
  • 蛋白質製劑次市場預測
  • 胰島素次市場
  • 生技仿製藥胰島素
  • 其他重組的荷爾蒙:促血紅細胞生長素、G-CSF、人體生長荷爾蒙
  • 血漿、重組的凝血因子
  • 干擾素
  • 酵素補充、其他蛋白質療法

第5章 單株抗體 (MAb) 次市場

  • 單株抗體次市場:科學、歷史背景
  • 暢銷前5名中,3個是MAb
  • 自體免疫MAb
  • 癌症MAb
  • 單株抗體次市場預測

第6章 融合蛋白品質製劑次市場

  • 科學、歷史背景
  • 融合蛋白品質製劑的差異化
  • Enbrel
  • Eylea
  • Orencia
  • Nplate
  • Eloctate
  • Nulojix
  • Arcalyst
  • 融合蛋白品質製劑的開發平台
  • 融合蛋白品質製劑次市場預測

第7章 再生醫療次市場

  • 再生醫療市場明細
  • 再生醫療次市場預測
  • 幹細胞治療次市場
  • 組織工程治療次市場
  • 基因治療次市場

第8章 主要國家的生技藥品市場

  • 各地區的預測
  • 美國
  • EU5個國家
  • 日本
  • BRIC

第9章 生技藥品市場定性分析與產業

  • SWOT分析
  • STEP分析

第10章 結論

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0130

Title:
Biologics Market Trends and Forecasts 2016-2026
Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Top Products Including Humira, Remicade, Lantus and Enbrel; and Assessment of R&D Including Sirukumab and NurOwn.

Biological Drugs - Discover Revenue Potentials Now, Benefiting Your Authority

Do you want to find how high biological drug sales can go? Visiongain's new analysis gives you those revenue forecasts to 2026 at overall world market, therapeutic class and national level. For biologics you discover data, opportunities, R&D and sales potentials.

Our updated report gives you multilevel revenue predictions for biopharmaceutical products from 2016, helping you stay ahead. There you investigate trends, results, technologies and expected products, benefiting your reputation for technological and commercial insight.

With our study you also assess the influence of biosimilars and other emerging treatments on that lucrative, expanding pharmaceutical industry and market.

Read on, then, to explore the biologics market, also seeing revenue prediction.

Forecasts and other analysis show you where the best sales opportunities exist

Our new report shows revenue forecasting to 2026, results, sales growth rates and market shares. In that 274 page study you explore quantitative and qualitative analyses, assessing sales potentials and R&D. You get 103 tables and 50 charts, gaining original research and analysis.

That way you assess clinical, technological and commercial trends, results and potentials such as these issues:

  • Why will the biologics market achieve revenue growth from 2016 to 2026, and what sales are possible from existing drugs and R&D?
  • When will that industry achieve worldwide revenues exceeding $300bn?
  • What treatment classes give the most commercial promise?
  • Who are the best-placed companies in the biopharma industry?
  • Where are the most important and promising countries for selling those treatments, and what future sales can leading national markets give?
  • How will biological drug producers serve regulators, doctors, patients and payers from 2016 to 2026, also benefiting the pharma industry?

Opportunities in biologics to enrich drug developers, producers and marketers

In 2015 eight of the top ten best-selling drugs were biologics. Many opportunities remain for products based on proteins and related biopharma technologies.

Our study lets you discover what segments are most likely to prosper, from 2016 to 2026, through forecasted sales. See what the future holds and how you can gain.

Why struggle to find data to help your work? Instead help your research, analyses, plans, proposals and presentations now. With visiongain's new investigation see how you could save time and benefit your reputation for commercial insight.

The following sections show how our new investigation benefits your work.

Predictions for that world market, submarkets and products

Along with revenue prediction for the overall world market for biologics, our study shows forecasts from 2016 to 2026 for 13 individual submarkets:

  • Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
  • Monoclonal antibodies (mAbs)
  • Fusion proteins
  • Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
  • Vaccines.

In addition you gain revenue forecasts for 18 leading products, including Lantus, Humalog, Avonex, Rebif, Humira, Remicade, Herceptin and Enbrel.

Our new investigation also discusses what stimulates and restrains sales of biologics. You explore that industry, seeing what segments and products can achieve the most success. Discover, from 2016, how pharmaceutical companies, patients and healthcare providers can benefit.

That study also divides its overall world forecast into geographical segments.

National markets for biopharmaceuticals - what does the future hold for sales?

Our report predicts rising demand for biological drugs in developed and developing countries. Discover what sales results and expansion are possible from 2016.

The analyses show you overall biologic revenue forecasts to 2026 for 11 national markets:

  • United States
  • Japan
  • Germany, France, United Kingdom, Italy and Spain (EU5)
  • Brazil, Russia, India and China (BRIC).

In our study you assess the biologic industry's future - needs, developments, demands and opportunities.

Our work explores issues affecting biopharma companies, influencing their results.

Forces affecting the biological drugs industry - what shapes its present and future?

The new report discusses pressures, opportunities and other events affecting the biologics industry and market from 2016, including these influences:

  • Research and development, especially potentials of recombinant DNA technology and emerging processes to benefit patients
  • Needs and opportunities for developing biologics, including rising prevalence of cancers, autoimmune and neurodegenerative disorders
  • Data exclusivity and patent challenges for biopharmaceuticals
  • New products, including Tresiba, Toujeo and Abasaglar
  • Next-generation biologics - explore competition, technological races and challenges, seeing what is possible.

Our study discusses other aspects of biologics too, including these forces:

  • Anti-cancer agents, erythropoietins, G-CSF and human growth hormones - investigate prospects for therapeutic classes
  • Treatments for haemophilia, diabetes, anaemia, bleeding disorders, wet AMD, multiple sclerosis, arthritis and other chronic diseases
  • Pricing, reimbursement, clinical efficacy and other challenges - explore regulators' and other healthcare payers' demands for biologics, including biosimilars and interchangeable biological products
  • Collaborations, partnerships and networks shaping biopharma.

With our new analysis you assess that industry's strengths, weaknesses, opportunities and threats. See what is happening. That way you explore what restricts and stimulates companies developing, manufacturing, marketing and selling biological medicines.

Companies and 2020 market forecast - what overall revenue potential?

From 2016, biological product launches hold great potential for investments, demand and sales. Our study predicts the world market for those drugs will reach $248 billion in 2020, with strong revenue expansion from 2016 to 2026. See how high revenues can go.

With our study you assess what biotechnologies, products and companies hold most potential, including these organisations:

  • Amgen
  • Bayer
  • Eli Lilly
  • GSK
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Novo Nordisk
  • Pfizer
  • Roche
  • Sanofi.

Biologics constitute 19% of the global pharmaceutical market. From 2016 there will arise many more opportunities, especially from drug launches. See what is possible.

Our work shows you commercial possibilities for biological drugs, helping you stay ahead in knowledge and succeed.

5 main ways Biologics Market Trends and Forecasts 2016-2026 helps your work

In these five main ways, our new study benefits your research, analyses, decisions, proposals and presentations:

  • Revenues to 2026 for biologics at overall world level - discover outlooks for development, production, marketing and sales
  • 13 submarkets' and 18 leading products' revenues to 2026 - investigate segments at world level, finding the most lucrative and fast-rising products
  • Forecasts to 2026 for 11 national markets in the Americas, Europe and Asia - assess developed and developing countries for potential revenues
  • Prospects for established competitors and rising companies - explore portfolios, results, strategies, R&D, partnerships and outlooks for success
  • Analysis of what stimulates and restrains biologic producers - investigate challenges, strengths and competition, helping you stay ahead and succeed.

That investigation, by our in-house analysts in the UK, gives knowledge to benefit your work. Our study shows information you find nowhere else.

Independent analysis to benefit your authority on pharma biotechnology

Our report provides independent analysis. It gives competitive intelligence found only in our study, helping you assess technological and commercial prospects.

With that study you are less likely to fall behind in information or miss opportunity. Discover how you could benefit your analyses, plans and decisions, also saving time and helping your influence.

Explore the future of biopharmaceuticals. In our study you find biologic data, trends, opportunities and sales predictions. Stay ahead by getting that new report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Biologics Overview
  • 1.2. Why you Should Read this Report
  • 1.3. How this Report Delivers
  • 1.4. Main Questions Answered by this Report
  • 1.5. Who is this Report for?
  • 1.6. Research and Analysis Methods
  • 1.7. Frequently Asked Questions (FAQ)
  • 1.8. Some Associated Reports
  • 1.9. About Visiongain

2. Introduction to the Biologics Market and Key Concepts

  • 2.1. Biologics: Large and Complex Products
  • 2.2. A Brief History of Biological Drug Development
  • 2.3. Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
  • 2.4. What are Biosimilars?
    • 2.4.1. Brief History of Biosimilars
    • 2.4.2. What are Interchangeable Biological Products and how do They Differ from Biosimilars?
    • 2.4.3. Why Many Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars
    • 2.4.4. What Share of the Overall Biologics Market do they Currently Hold?
  • 2.5. What are Next-Generation Biologics? What Share of the Overall Biologics Market do they Currently Hold?
  • 2.6. Marginal Cases
  • 2.7. Vaccines Market

3. The Global Biologics Market 2016-2026

  • 3.1. The Global Biologics Market Forecast, 2016-2026
  • 3.2. What Factors Will Drive Growth in the Biologics Market?
  • 3.3. Ageing Population and the Rise of Chronic Disease
  • 3.4. Eight of the Top Ten Best-Selling Drugs in 2015 were Biologics
  • 3.5. Biologics Constitute 19% of the Global Pharmaceutical Market - Further Launches will Drive Market
  • 3.6. Biosimilars - Both an Opportunity and a Threat
  • 3.7. What Factors will Restrain Growth in the Biologics Market?
  • 3.8. High Costs in the Face of Declining National Healthcare Budgets
  • 3.9. In Some Areas, Clinical Efficacy is not Superior Enough to Justify the Price Gap
  • 3.10. Over $67bn worth of Biologic Patents due to Expire by 2020
  • 3.11. Administration is Often not as Convenient
  • 3.12. Biologics Market: Submarket Forecasts 2016-2026

4. Protein Therapeutics Submarket 2016-2026

  • 4.1. Largest and Most Diverse Submarket
  • 4.2. Proteins have been used Medicinally since the 19th Century
    • 4.2.1. Recombinant DNA Technology - The Major Breakthrough in the use of Protein Drugs
  • 4.3. Protein Therapeutics Submarket Forecast 2016-2026
  • 4.4. Insulin Submarket 2016-2026
    • 4.4.1. The First Protein Therapeutic
    • 4.4.2. 430 Million People Expected to be Diagnosed with Diabetes by 2030
    • 4.4.3. The Status of the Market in 2015: Novo Nordisk, Sanofi and Eli Lilly Dominate
    • 4.4.4. Insulin Submarket Forecast 2016-2026
    • 4.4.5. Lantus: The Market Leading Drug by Far
      • 4.4.5.1. Lantus Revenue Forecast 2016-2026
    • 4.4.6. NovoLog/NovoRapid Revenue Forecast 2016-2026
    • 4.4.7. Humalog Revenue Forecast 2016-2026
    • 4.4.8. New Approvals and Pipeline
      • 4.4.8.1. Tresiba (Novo Nordisk)
      • 4.4.8.2. BIOD-123(Biodel)
  • 4.5. Biosimilar Insulin
    • 4.5.1. Approved Insulin Biosimilars
    • 4.5.2. Abasaglar/Basaglar/Insulin Glargine BS - The First Insulin Biosimilars to be Approved in Developed Markets. Delayed in the US
    • 4.5.3. Insulin Glargine in the Main Biosimilar Target - and there is Limited Development for the Other Targets
  • 4.6. Other Recombinant Hormones: Erythropoietins, G-CSF and Human Growth Hormone
    • 4.6.1. Erythropoietin
    • 4.6.2. First-Generation Therapies Launched in the 1980s
      • 4.6.2.1. Aranesp: Slowly Growing
      • 4.6.2.2. Epogen: Increases in Selling Price are No Longer Enough to Ward off Decline
      • 4.6.2.3. Procrit/Eprex: In Decline Since 2013
      • 4.6.2.4. NeoRecormon and Mircera (Roche) Provides Competition for Market Leader Amgen
      • 4.6.2.5. Safety Concerns for Erythropoietin-Stimulating Agents is Leading to Decreased Demand
      • 4.6.2.6. The Challenge from Oral Therapies is Coming
      • 4.6.2.7. Treating Anaemia in Patients with CKD - The Leading Use of EPO Therapies
      • 4.6.2.8. Many Biosimilar Epoetins Approved Around the World
    • 4.6.3. G-CSF
      • 4.6.3.1. G-CSF: Discovered 1983. Recombinant Forms Available Since 1991
      • 4.6.3.2. Amgen Leads the Market
      • 4.6.3.3. Neupogen and Neulasta Revenues, and the Onpro Kit
      • 4.6.3.4. Teva Aiming to Challenge Amgen's Dominance
      • 4.6.3.5. Facing Much Biosimilar Competition Around the World
    • 4.6.4. Human Growth Hormone
      • 4.6.4.1. Human Growth Hormone: First Extracted in 1958
      • 4.6.4.2. Novo Nordisk Dominates Market
      • 4.6.4.3. Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
      • 4.6.4.4. Multiple Biosimilars Available - Omnitrope is Market Leader
      • 4.6.4.5. Biosimilar Growth Hormones in Asia
    • 4.6.5. Other Recombinant Hormones Submarket Forecast 2016-2026
  • 4.7. Plasma and Recombinant Coagulating Factors
    • 4.7.1. Discovery of Plasma and Clotting Proteins
    • 4.7.2. Types of Recombinant Factor
    • 4.7.3. Clotting Factor Deficiency Diseases
    • 4.7.4. Baxter/Baxalta: Entered the Bleeding Disorders Market in 1992, Markets Various Leading Products
      • 4.7.4.1. Baxter: New Product Launches Include Rixubis and Obizur
    • 4.7.5. Novo Nordisk: Committed to Remaining a Leading Company in the Bleeding Disorders Market
      • 4.7.5.1. Novo Nordisk: Has filed for Approval for N9-GP and NovoEight is Doing Well
    • 4.7.6. Bayer: Markets Kogenate, Kogenate FS, and has Received FDA Approval for Kovaltry
    • 4.7.7. Limited Opportunities for Biosimilar Challenge
    • 4.7.8. Plasma and Recombinant Coagulating Factors Submarket Forecast 2016-2026
  • 4.8. Interferons
    • 4.8.1. Interferons: Key Antiviral and MS Therapies Since the 1990s
    • 4.8.2. Interferons for Treating Hepatitis: Its Influence is Decreasing
    • 4.8.3. Competition from Oral Protease and Polymerase Inhibitors
      • 4.8.3.1. Oral Therapies are Expensive
    • 4.8.4. Avonex: The Leading Interferon Therapy
      • 4.8.4.1. Avonex Revenue Forecast 2016-2026
    • 4.8.5. Rebif: Merck Attempting to Differentiate Rebif from Other Interferon Therapies
      • 4.8.5.1. Rebif Revenue Forecast 2016-2026
    • 4.8.6. Betaseron
    • 4.8.7. Plegridy: New Therapy with High Potential
    • 4.8.8. Biosimilar Interferons: None Approved in Developed Markets, but Many Available in Emerging Nations
    • 4.8.9. Interferon Submarket Forecast 2016-2026
  • 4.9. Enzyme Replacement and Other Protein Therapies Submarket
    • 4.9.1. Cerezyme: Genzyme's Leading Enzyme Replacement Therapy
    • 4.9.2. Myozyme and Lumizyme
    • 4.9.3. Fabrazyme and Aldurazyme
    • 4.9.4. Botulinum Toxin Brands Include Botox, Dysport and Xeomin
    • 4.9.5. Other Protein Therapeutics Pipeline
      • 4.9.5.1. Anthera Buys Sollpura from Eli Lilly, Phase 3 Results Expected Q4 2016
      • 4.9.5.2. Multikine (CEL-SCI)
      • 4.9.5.3. Vonapantiase (Proteon Therapeutics)
    • 4.9.6. Enzyme Replacement and Other Protein Therapeutics Submarket Forecast 2016-2026

5. Monoclonal Antibodies Submarket 2016-2026

  • 5.1. Monoclonal Antibodies Submarket: Scientific and Historical Background
    • 5.1.1. Natural Antibodies: Key to the Immune System
    • 5.1.2. From Serum Therapy to Monoclonal Antibodies
    • 5.1.3. Humanising the mAb
    • 5.1.4. MAbs have found Success in Treating Autoimmune Disorders, Cancers and Others Diseases - Great Potential for the Future
    • 5.1.5. MAbs for All? Technologies Come Off Patent
  • 5.2. Three out of the Top Five Best-Selling Drugs are mAbs
  • 5.3. Autoimmune mAbs
    • 5.3.1. Past Approvals
    • 5.3.2. Humira - The World's Best-Selling Prescription Drug
      • 5.3.2.1. AbbVie Plans to Drive Growth Through New Indications
      • 5.3.2.2. Positive Opinion from CHMP for Treatment of Non-Infectious Uveitis
      • 5.3.2.3. Recently Approved for Hidradenitis Suppurativa in the US and Europe
      • 5.3.2.4. Biosimilar Adalimumab: Patents Protect Humira in Developed Markets for Now
      • 5.3.2.5. Humira Revenue Forecast 2016-2026
    • 5.3.3. Remicade: Second Only to Humira
      • 5.3.3.1. 2015 Revenue for J&J and Merck
      • 5.3.3.2. Has Defended Revenues well but now has to Deal with Biosimilar Competition
      • 5.3.3.3. Patent Dance in US
      • 5.3.3.4. Biosimilar Infliximab: Multiple Launches
      • 5.3.3.5. Remicade Revenue Forecast 2016-2026
    • 5.3.4. Stelara: Double Blockbuster
      • 5.3.4.1. Stelara Revenues 2013-2015
      • 5.3.4.2. Orphan Drug Designation for paediatric Crohn's Disease
    • 5.3.5. Simponi and Simponi Aria: Another Blockbuster mAb for J&J and Merck & Co.
      • 5.3.5.1. 2015 and 2014 Revenue Breakdown
    • 5.3.6. Tysabri: Blockbuster Drug's High Efficacy Offsets its Risks
      • 5.3.6.1. Tysabri: Revenues 2011-2015
      • 5.3.6.2. Tysabri Revenue Forecast 2016-2026
    • 5.3.7. Xolair: New Indication, and Revenue Breakdown
    • 5.3.8. Actemra/RoActemra: Strong Growth in All Regions
    • 5.3.9. Cimzia: Blockbuster Which has been Used by Over 90,000 Patients
    • 5.3.10. Autoimmune mAbs Pipeline: RA is the Main Target
      • 5.3.10.1. Sarilumab (REGN88/SAR153191) by Regeneron and Sanofi: BLA Accepted for Review and Decision Expected by November 2016
      • 5.3.10.2. Sirukumab (CNTO-136) by J&J and GSK: Multiple Phase 3 Studies Around the World
      • 5.3.10.3. Clazakizumab: Developed by Alder Biopharmaceuticals and BMS but now Licensed to Vitaeris
      • 5.3.10.4. Tregalizumab (BT-061) by Biotest: AbbVie Backs out After Poor Results
      • 5.3.10.5. Mavrilimumab by AstraZeneca: Approaching Phase 3
      • 5.3.10.6. Zinbryta (daclizumab high-yield process) by Biogen and AbbVie: Positive Opinion from CHMP
      • 5.3.10.7. Lebrikizumab by Roche: Undergoing Phase 3 After Positive Phase 2b Results
      • 5.3.10.8. Sifalimumab (MEDI-545) by AstraZeneca: Hasn't made the cut for Phase 3
      • 5.3.10.9. Anifrolumab by AstraZeneca
  • 5.4. Oncology mAbs
    • 5.4.1. Past Approvals
    • 5.4.2. Rising Incidence of Cancer will Drive Demand
    • 5.4.3. Rituxan: The World's Leading Anti-Cancer mAb
    • 5.4.4. Biosimilar Rituximab: Two Candidates Await Approval in Europe
    • 5.4.5. Gazyva: Roche's Successor to Rituxan, Will Help to Retain Revenues in Face of Biosimilar Competition
      • 5.4.5.1. Approval for Follicular Lymphoma and Being Investigated for Other Indications
    • 5.4.6. Avastin: Growing under CER, Through New Indications
      • 5.4.6.1. Controversy over Off-Label Avastin use: Roche is Backed up by Incidents in India, and Opinion of EFPIA
      • 5.4.6.2. Biosimilar Bevacizumab: Late Patent Expiry is a Blessing for Roche, Although Various Biosimilars in Development
    • 5.4.7. Herceptin: Breast Cancer Blockbuster
      • 5.4.7.1. Pricing Challenges in Emerging Markets, and 2015 Revenues
      • 5.4.7.2. Roche Builds Franchise of Anti-HER2 mAbs Around Herceptin
      • 5.4.7.3. Herceptin Revenue Forecast 2016-2026
      • 5.4.7.4. Biosimilar Trastuzumab
    • 5.4.8. Kadcyla
      • 5.4.8.1. Mixed Results from Different Clinical Trials
      • 5.4.8.2. Kadcyla Sales Forecast 2016-2026
    • 5.4.9. Perjeta
      • 5.4.9.1. Positive Results from Different Clinical Trials
      • 5.4.9.2. Perjeta Revenue Forecast 2016-2026
    • 5.4.10. Yervoy: Bristol-Myers Squibb's Leading Anti-Cancer mAb, Keeps High Revenues, but with Decline over 2014
    • 5.4.11. Opdivo: Big Potential for Bristol-Myer Squibb's PD-1 Inhibitor
      • 5.4.11.1. Good News and Bad News for NSCLC from CheckMate Trials
      • 5.4.11.2. Cyramza (Eli Lilly): Approved in Three Additional Indications Since its First Approval in April 2014
    • 5.4.12. Oncology mAbs: New Approvals and Pipeline
      • 5.4.12.1. Empliciti (Elotuzumab) by Bristol-Myers Squibb and AbbVie): Recently Approved
      • 5.4.12.2. Avelumab: Pfizer and Merck KGaA Team Up to Develop Their Own Anti-PD mAb
      • 5.4.12.3. Unituxin (United Therapeutics) Receives FDA Approval March 2015
      • 5.4.12.4. SAR3419(coltuximab ravtansine) (anti-CD19, Sanofi)
  • 5.5. Monoclonal Antibodies Submarket Forecast 2016-2026

6. Fusion Proteins Submarket 2016-2026

  • 6.1. Scientific and Historical Background
  • 6.2. Differentiating Fusion Proteins
  • 6.3. Enbrel: The First FP to be Approved, in 1998
    • 6.3.1. Gradually Approved for Additional Indications
    • 6.3.2. The Leading Fusion Protein
    • 6.3.3. Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
    • 6.3.4. Multiple Biosimilars Available in Emerging Markets
    • 6.3.5. Enbrel Revenue Forecast 2016-2026
  • 6.4. Eylea: Blockbuster FP Treatment for Wet AMD
    • 6.4.1. Eylea Revenue Forecast 2016-2026
  • 6.5. Orencia: Grows Blockbuster Revenues by 14% for Second Year in a Row
  • 6.6. Nplate: Generates Half a Billion in Revenues for Amgen
  • 6.7. Eloctate: Approved June 2014, Fulfils Unmet Need in the Haemophilia Community
  • 6.8. Nulojix: Bristol-Myers Squibb's Therapy for Preventing Organ Rejection
  • 6.9. Arcalyst by Regeneron Pharmaceuticals: For Very Rare Conditions
  • 6.10. Fusion Proteins Pipeline
    • 6.10.1. Trebananib (Amgen)
    • 6.10.2. Sotatercept by Acceleron Pharma and Celgene Corporation - Currently Undergoing Eight Clinical Trials
    • 6.10.3. Blisibimod (Anthera Pharmaceuticals) for the Treatment of Various Autoimmune Diseases, in Late Stage Development
  • 6.11. Fusion Protein Submarket Forecast 2016-2026

7. Regenerative Medicines Submarket 2016-2026

  • 7.1. Regenerative Medicines Market Breakdown
  • 7.2. Regenerative Medicines Submarket Forecast, 2016-2026
  • 7.3. Stem Cell Therapies Submarket, 2016-2026
    • 7.3.1. Stem Cells: Scientific Breakdown
    • 7.3.2. Stem Cell Therapies Submarket Breakdown
    • 7.3.3. Haematopoietic Stem Cell Transplantation: Over 80,000 Carried out in 2014
      • 7.3.3.1. From Procedures to Products: Cord Blood Stem Cell Approvals
    • 7.3.4. Osteocel Plus: The Leading Stem Cell Orthobiologic
      • 7.3.4.1. Osteocel Plus Revenue Forecast 2016-2026
    • 7.3.5. Trinity Evolution and Trinity Elite
      • 7.3.5.1. Trinity Evolution and Trinity Elite Revenue Forecast 2016-2026
    • 7.3.6. MSC-100-IV (Previously Known as Prochymal): World's First Approved Stem Cell Drug Outside of South Korea
      • 7.3.6.1. An Important Role to Play in the Future of HSCT, and also Wins Approval in Japan through Partner
    • 7.3.7. CARTISTEM (MEDIPOST): The World's First Allogeneic Stem Cell Drug
    • 7.3.8. Hearticellgram-AMI (Pharmicell): One of the First Approved Cardiovascular Stem Cell Treatments in the World
    • 7.3.9. Stem Cell Therapies Pipeline
      • 7.3.9.1. Cx601 by TiGenix: Marketing Authorisation Application has been Submitted to EMA
      • 7.3.9.2. CardiAMP (BioCardia) for Heart Failure: Undergoing Phase 3 Trial and has Received Grant from MSCRF
      • 7.3.9.3. NurOwn (BrainStorm Cell Therapeutics): Neurotrophic Factor -Releasing Stem Cells for ALS in Phase 2 and Due to end Soon
      • 7.3.9.4. Agenmestencel-T (Apceth): Phase 1/2 Due to end Soon
    • 7.3.10. Stem Cell Therapies Submarket Forecast 2016-2026
  • 7.4. Tissue Engineering Therapies Submarket 2016-2026
    • 7.4.1. Tissue Engineering - In Vitro Manipulation for Therapeutic Purposes
    • 7.4.2. Current Status of the Market
    • 7.4.3. Apligraf: The Leading Product
      • 7.4.3.1. Apligraf Revenue Forecast 2016-2026
    • 7.4.4. Dermagraft: Organogenesis Further Strengthens Position Through this 2014 Acquisition
      • 7.4.4.1. Dermagraft Revenue Forecast 2016-2026
    • 7.4.5. ReCell
    • 7.4.6. MySkin and CyroSkin
    • 7.4.7. Tissue Engineering Therapies Pipeline
      • 7.4.7.1. NeoCart by Histogenics: Undergoing Phase 3 Trial for Knee Cartilage Repair
      • 7.4.7.2. Extracorporeal Bio-Artificial Liver Therapy by Vital Therapies
      • 7.4.7.3. StrataGraft by Stratatech Corporation Demonstrates Positive Top-Line Results
    • 7.4.8. Tissue Engineering Therapies Submarket Forecast 2016-2026
  • 7.5. Gene Therapies Submarket 2016-2026
    • 7.5.1. Gene Therapy: Historical and Scientific Background
    • 7.5.2. Harnessing Infectivity: Viral Vectors in Gene Therapy
    • 7.5.3. Approved Gene Therapy Products
      • 7.5.3.1. Gendicine: The World's First Commercial Gene Therapy Product
      • 7.5.3.2. Oncorine: First Oncolytic Viral Therapy
      • 7.5.3.3. Neovasculgen: Russia's First Gene Therapy
      • 7.5.3.4. Neovasculgen: Drop in Revenues in 2015, but HSCI Predicts Notable Increases as Product is Added to VED List
      • 7.5.3.5. Glybera: The First Gene Therapy for Western Markets, Although Has Abandoned Hope of Receiving FDA-Approval
      • 7.5.3.6. IMLYGIC
      • 7.5.3.7. IMLYGIC: Clinical Trials and Development Efforts
      • 7.5.3.8. IMLYGIC: Revenue Forecast 2016-2026
    • 7.5.4. Gene Therapies Pipeline
      • 7.5.4.1. AAV2-hRPE65v2 (Spark Therapeutics): Undergoing Phase 3 Trial
      • 7.5.4.2. AdV-tk/ProstAtak (Advantagene): Phase 3
      • 7.5.4.3. Collategene (beperminogene perplasmid, AMG0001) - (AnGes MG/Vical)
    • 7.5.5. Gene Therapy Submarket Forecast 2016-2026

8. Leading National Markets for Biologics 2016-2026

  • 8.1. Regional Forecasts for the Global Biologics Market 2016-2026
  • 8.2. US Biologics Market 2016-2026
    • 8.2.1. The Major National Market
    • 8.2.2. Value-Based Pricing in the US
    • 8.2.3. Regulation of Biologics in the US
    • 8.2.4. US Biosimilars Market
      • 8.2.4.1. FDA Finalises Biosimilar Guidelines and Biosimilar Naming
    • 8.2.5. US Biologics Market Forecast 2016-2026
  • 8.3. EU5. Biologics Market 2016-2026
    • 8.3.1. Current Composition and Future Outlook
    • 8.3.2. European Biosimilar Market
      • 8.3.2.1. History of EMA Guidelines and Updates
    • 8.3.3. EU5. Market Forecast by Nation 2016-2026
  • 8.4. Japanese Biologics Market 2016-2026
    • 8.4.1. Current Status of the Japanese Biologics Market
    • 8.4.2. Japanese Biosimilar Market
    • 8.4.3. Japanese Biologics Market Forecast 2016-2026
  • 8.5. BRIC National Biologic Markets 2016-2026
    • 8.5.1. BRIC Markets Overview
    • 8.5.2. BRIC Biologic Market Forecast 2016-2026
      • 8.5.2.1. Unique Challenges Faced by the Biologics Industry have led to Current Composition of the BRIC Biologic Market
      • 8.5.2.2. Future Outlook
      • 8.5.2.3. BRIC Nation Market Shares in the Global Biologics Market will Nearly Double During the Forecast Period
    • 8.5.3. Brazil: Disproportionately High Government Spending on Biologics
      • 8.5.3.1. Brazilian Government Eager to Promote Domestic Biologic and Biosimilar Development
    • 8.5.4. Russia: Another Government Which is Eager to Increase Domestic Biological Drug Development
    • 8.5.5. India: Biologics Market Behind that of Other BRIC Nations, but Biosimilars Submarket Thriving
      • 8.5.5.1. CDSCO Guidelines Released in 2012
    • 8.5.6. China: Expected to the Largest BRIC Market for Biologics by 2020
      • 8.5.6.1. The Largest National Biosimilar Market in the World

9. Qualitative Analysis of the Biologics Market and Industry

  • 9.1. SWOT Analysis of the Global Biologics Market and Industry
    • 9.1.1. Strengths
    • 9.1.2. Opportunities
    • 9.1.3. Weaknesses
    • 9.1.4. Threats
  • 9.2. STEP Analysis of the Global Biologics Market and Industry
    • 9.2.1. Social Factors
    • 9.2.2. Technological Developments
    • 9.2.3. Economic Pressures
    • 9.2.4. Political Issues

10. Conclusions

  • 10.1. Biologics Market to Achieve Steady Growth Throughout the Forecast Period
  • 10.2. Changes in Market Composition: mAbs to Become Leading Submarket
  • 10.3. The Emergence of Biosimilars
  • 10.4. Challenges for the Market
  • 10.5. Some Associated Reports

List of Tables

  • Table 1.1: Currency Exchange Rates: Average Exchange Rate to USD for 2014 and 2015
  • Table 2.1: First Approvals for Recombinant Protein Therapies, 1982-1993
  • Table 3.1: Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 3.2: Global Biologics Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 3.3: Top Ten Best-Selling Drugs in 2015: Revenue ($bn), Share of Biologics Market (%)
  • Table 3.4: Patent Status of Selected Leading Biologics
  • Table 3.5: Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 3.6: Submarkets within the Biologics Market, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 4.1: First Approvals for Recombinant Protein Therapies, 1982-1993
  • Table 4.2: Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.3: Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.4: Diabetes Prevalence in Leading National Markets, 2014
  • Table 4.5: Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.6: Insulin Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.7: Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.8: Lantus Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.9: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.10: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.11: Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.12: Humalog Revenue Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.13: Selected Insulin Biosimilars which have been Approved and Launched
  • Table 4.14: Selected EPO Biosimilars Approved in India
  • Table 4.15: European Biosimilar Approvals: G-CSF
  • Table 4.16: Selected Filgrastim Biosimilars Approved Worldwide, 2016
  • Table 4.17: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.18: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 4.19: Selected Coagulating Factors Significant in Segment
  • Table 4.20: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.21: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.22: Selected Approved Branded Interferon Therapies
  • Table 4.23: Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.24: Avonex Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.25: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 4.26: Rebif Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 4.27: Selected Interferon Alfa Biosimilars Approved Worldwide, 2016
  • Table 4.28: Selected Interferon Beta Biosimilars Approved Worldwide, 2016
  • Table 4.29: Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.30: Interferon Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 4.31: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 4.32: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.1: Regions of an Antibody
  • Table 5.2: Natural Antibody Mechanisms of Action
  • Table 5.3: Top Five Best-Selling Drugs, 2015: Revenue ($bn)
  • Table 5.4: Selected Biosimilar Adalimumab Candidates
  • Table 5.5: Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.6: Humira Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.7: Remicade 2015 Revenue Breakdown: Revenue ($bn), Percentage Change over 2014 (%)
  • Table 5.8: Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.9: Remicade Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.10: Stelara Revenue 2013-2015: Revenue ($bn), AGR (%),
  • Table 5.11: Total Tysabri Revenues 2011-2015, Revenues ($bn), AGR (%), CAGR (%)
  • Table 5.12: Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.13: Tysabri Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.14: Xolair Revenue Breakdown (between Roche and Novartis): Revenue ($bn), AGR (%), 2014-2015
  • Table 5.15: Selected Ongoing Sirukumab (CNTO-136) Clinical Trials, 2016
  • Table 5.16: Selected Ongoing Lebrikizumab Clinical Trials, 2016
  • Table 5.17: Selected Ongoing Anifrolumab Clinical Trials, 2016
  • Table 5.18: Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.19: Herceptin Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.20: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.21: Kadcyla Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.22: Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.23: Perjeta Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 5.24: FDA-Approved Indications for Cyramza
  • Table 5.25: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 5.26: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 6.1: Amgen's US Patents and Expiry Dates for Enbrel
  • Table 6.2: Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 6.3: Enbrel Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 6.4: Eylea Revenue Breakdown 2015: Regeneron and Bayer
  • Table 6.5: Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 6.6: Eylea Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 6.7: Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 6.8: Fusion Proteins Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 7.1: Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 7.2: Regenerative Medicines Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 7.3: Potency and Source of Stem Cells
  • Table 7.4: Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 7.5: Osteocel Plus Revenue Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 7.6: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 7.7: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 7.8: Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 7.9: Stem Cell Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 7.10: Apligraf Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 7.11: Apligraf Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 7.12: Dermagraft Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 7.13: Dermagraft Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 7.14: Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 7.15: Tissue Engineering Therapies Submarket: Revenues ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 7.16: IMLYGIC Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2020
  • Table 7.17: IMLYGIC Revenue Forecast: Revenue ($m), AGR (%), CAGR (%), 2021-2026
  • Table 7.18: Gene Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
  • Table 7.19: Gene Therapies Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2021-2026
  • Table 8.1: Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
  • Table 8.2: Regional Forecasts for the Global Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2021-2026
  • Table 8.3: US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2015-2020
  • Table 8.4: US Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2021-2026
  • Table 8.5: European Biosimilar Approvals, 2006-2016
  • Table 8.6: EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2015-2020
  • Table 8.7: EU5 Biologics Market: Revenues ($bn), AGR (%), CAGR (%), EU5 Market Share (%), 2021-2026
  • Table 8.8: Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2015-2020
  • Table 8.9: Japanese Biologics Market: Revenues ($bn), AGR (%), CAGR (%), Global Market Share (%), 2021-2026
  • Table 8.10: BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2015-2020
  • Table 8.11: BRIC Biologics Market: Revenues ($bn), AGR (%), CAGR (%), BRIC Market Share (%), 2021-2026

List of Figures

  • Figure 1.1: Forecasted Submarkets of the Biologics Market
  • Figure 3.1: Global Biologics Market Forecast: Revenues ($bn), 2015-2026
  • Figure 3.2: Submarkets within the Biologics Market, Forecast: Revenues ($bn), 2015-2026
  • Figure 4.1: Protein Therapeutics Submarket Forecast: Revenues ($bn), 2015-2026
  • Figure 4.2: Diabetes Prevalence in Leading National Markets, 2014
  • Figure 4.3: Insulin Submarket Forecast: Revenues ($bn), 2015-2026
  • Figure 4.4: Lantus Revenue Forecast: Revenues ($bn), 2015-2026
  • Figure 4.5: NovoLog/NovoRapid Revenue Forecast: Revenues ($bn), 2015-2026
  • Figure 4.6: Humalog Revenue Forecast: Revenues ($bn), 2015-2026
  • Figure 4.7: Other Recombinant Hormones Submarket Forecast: Revenues ($bn), 2015-2026
  • Figure 4.8: Plasma and Recombinant Coagulating Factors Submarket Forecast: Revenues ($bn), 2015-2026
  • Figure 4.9: Avonex Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 4.10: Rebif Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 4.11: Interferon Submarket Forecast: Revenues ($bn), 2015-2026
  • Figure 4.12: Enzyme Replacement and Other Protein Therapeutics Submarket Forecast: Revenues ($bn), 2015-2026
  • Figure 5.1: Humira Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 5.2: Remicade Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 5.3: Stelara Revenue 2013-2015: Revenue ($bn)
  • Figure 5.4: Total Tysabri Revenues 2011-2015, Revenues ($m)
  • Figure 5.5: Tysabri Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 5.6: Herceptin Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 5.7: Kadcyla Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 5.8: Perjeta Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 5.9: Monoclonal Antibodies Submarket Forecast: Revenue ($bn), 2015-2026
  • Figure 6.1: Enbrel Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 6.2: Eylea Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 6.3: Fusion Proteins Forecast: Revenue ($bn), 2015-2026
  • Figure 7.1: Regenerative Medicines Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.2: Osteocel Plus Revenue Forecast: Revenue ($bn), 2015-2026
  • Figure 7.3: Trinity Evolution and Trinity Elite Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 7.4: Stem Cell Therapies Market Forecast: Revenue ($bn), 2015-2026
  • Figure 7.5: Apligraf Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 7.6: Dermagraft Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 7.7: Tissue Engineering Therapies Submarket: Revenues ($bn), 2015-2026
  • Figure 7.8: IMLYGIC Revenue Forecast: Revenue ($m), 2015-2026
  • Figure 7.9: Gene Therapies Market Forecast: Revenue ($bn), 2015-2026
  • Figure 8.1: Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2015
  • Figure 8.2: Regional Breakdown of Global Biologics Market: Revenues ($bn), Market Share (%), 2026
  • Figure 8.3: Regional Forecasts for Global Biologics Market: Revenues ($bn), 2015-2026
  • Figure 8.4: US Biologics Market: Revenues ($bn), 2015-2026
  • Figure 8.5: EU5 Market Breakdown: Market Share (%), 2015
  • Figure 8.6: EU5 Biologics Market: Revenues ($bn), 2015-2026
  • Figure 8.7: Japanese Biologics Market: Revenues ($bn), 2015-2026
  • Figure 8.8: Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2015
  • Figure 8.9: BRIC Biologics Market: Revenues ($bn), 2015-2026
  • Figure 8.10: Biologics Market Breakdown: Revenues ($bn), Market Share (%), 2026
  • Figure 9.1: SWOT Analysis of Biologics Market and Industry, 2016-2026
  • Figure 9.2: STEP Analysis of Biologics Market and Industry, 2016-2026
  • Figure 10.1: Global Biologics Market Forecast: Revenues ($bn), Annual Growth Rate (%), 2015-2026
  • Figure 10.2: Breakdown by Submarket: Revenues ($bn), 2015-2026

Companies Listed

  • 3SBio
  • AbbVie
  • Acceleron Pharma
  • Accord Healthcare
  • Aché
  • Actavis
  • Advanced BioHealing
  • Advantagene
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Alder Biopharmaceuticals
  • Allergan
  • Alteogen
  • Amega Biotech
  • Amgen
  • AnGes
  • Anthera Pharmaceuticals
  • Apceth
  • Apotex
  • Aryogen
  • Astellas Pharma
  • AstraZeneca
  • Avita Medical
  • Baxalta
  • Baxter
  • Bayer
  • Beijing Four Rings
  • Beijing SL Pharmaceutical
  • Benda Pharmaceuticals
  • Biocad
  • BioCardia
  • Biocon
  • Biodel
  • Biogen
  • Bionovis
  • Biosidus
  • Biotest
  • Bioton
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Cambridge Antibody Technology
  • CCL Pharmaceuticals
  • Celgene Corporation
  • Celltrion
  • CEL-SCI
  • Centocor Ortho Biotech
  • Central Drugs Standard Control Organisation
  • Children's Oncology Group
  • China Food and Drug Administration
  • CHMP
  • Chugai
  • CinnaGen
  • ClinImmune Labs
  • CSL Behring
  • CT Arzneimittel
  • Cystic Fibrosis Foundation Therapeutics Inc
  • Dako
  • Dendreon
  • Dong-A
  • Dong-A Pharmaceutical
  • Dr. Reddy's Laboratories
  • Duke University School of Medicine
  • Eli Lilly
  • EMA
  • Emcure Pharmaceuticals
  • EMS
  • Epirus
  • European Federation of Pharmaceutical Industries and Associations
  • Europharm
  • FDA
  • FibroGen
  • FierceBiotech
  • Finox Biotech
  • Fuji Pharma
  • Galencia
  • Gan & Lee
  • Genentech
  • GenSci
  • Gilead Sciences
  • GSK
  • Hangzhou Jiuyuan Gene Engineering Co.
  • Hanwha Chemical
  • Hexal
  • Hindustan Antibiotic
  • Histogenics
  • Hospira
  • Human Genome Sciences
  • Human Stem Cells Institute
  • Hypermarcas
  • Immunex Corporation
  • Innovare R&D
  • Intas Biopharmaceuticals
  • Ipsen
  • Janssen
  • JingYuan Bio
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Laboratorios Delta
  • LG Life Sciences
  • LifeSouth Community Blood Centers
  • Massachusetts General Hospital
  • Medice
  • MEDICE Arzneimittel Pütter
  • MEDIPOST
  • Medtronic
  • Merck & Co.
  • Merck KGaA
  • Merz Pharma
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Musculoskeletal Transplant Foundation (MTF)
  • Mylan
  • New York Blood Center
  • NHS
  • NICE
  • Nippion Kayaku
  • Novartis
  • Novo Nordisk
  • NuVasive
  • Oanda
  • Organogenes
  • OrLife Bio
  • Orthofix
  • Orygen
  • Pfizer
  • Pharmicell
  • Pharmstandard
  • Probiomed
  • Proteon Therapeutics
  • Qilu Pharmaceutical
  • Ranbaxy
  • Ratiopharm
  • Regeneron Pharmaceuticals
  • Regenerys
  • Reliance Life Sciences
  • Rentschler Biotechnologie.
  • Roche
  • Samsung Bioepis
  • Sandoz
  • Sanofi
  • Saudi Food and Drug Authority
  • Schering-Plough
  • SciGen
  • Shandong Kexing Pharma
  • Shanghai CP Guojian Pharmaceutical
  • Shanghai Fosun
  • Shanghai Sunway Biotech
  • Shantha Biotechnics
  • Shire
  • Sicor Biotech
  • Smith and Nephew
  • Spark Therapeutics
  • SSN Cardinal Glennon Children's Medical Center
  • Stada
  • Stanford University
  • Stragen Pharma
  • Stratatech Corporation
  • Swiss Re
  • Teva
  • The European Generic medicines Association (EGA)
  • The European Group for Blood and Marrow Transplantation (EBMT)
  • Tianjin Hualida Biotechnology
  • TiGenix
  • Tonghua Dongbao
  • Toronto University
  • UCB
  • UCSF (University of California, San Francisco)
  • União Química
  • UniQure
  • United Therapeutics
  • University of Colorado Cord Blood Bank
  • University of Tokyo
  • US Center for Disease Prevention and Control (CDC)
  • Vertex Pharmaceuticals
  • Vital Therapies Inc.
  • Wall Street Journal
  • Walter and Eliza Hall Institute
  • Wockhardt
  • World Bank
  • Wyeth-Ayerst Laboratories
  • Xiamen Amoytop Biotech
  • Yonsei University
  • Zenotech
  • Zydus Biovation
  • Zydus Cadila
Back to Top